Paul C. Tumeh - Concepedia

Author

Paul C. Tumeh

University of California, Los Angeles

Also Known As

Holbrook E. Kohrt, Paul C Tumeh, Paul C. Tumeh, Paul Camille Tumeh*, Paul Tumeh

100

Publications

16.7K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles UCLA Jonsson Comprehensive Cancer Center University of California, San Francisco Angeles Clinic and Research Institute Adaptive Biotechnologies (United States)

About

Paul C. Tumeh is an author at University of California, Los Angeles specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	7K
2	Health Sciences	2	2	30
3	Cell Biology	2	2	257
4	Allergy	1	1	91
5	Cellular Therapies	1	1	25

Paul C. Tumeh

Publications

16.4K

Citations

H-Index

Page 1

	Year	Citations
PD-1 blockade induces responses by inhibiting adaptive immune resistance Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, Nature MedicineImmunologyTumor ImmunityAutoimmunityImmunomodulation	2014	6.5K
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid, Caroline Robert, Adil Daud, New England Journal of Medicine	2013	3.4K
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma Jesse M. Zaretsky, Ángel García-Díaz, Daniel Sanghoon Shin, New England Journal of Medicine	2016	3.1K
Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations Daniel Sanghoon Shin, Jesse M. Zaretsky, Helena Escuin-Ordinas, Cancer Discovery	2016	1.2K
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC Paul C. Tumeh, Matthew D. Hellmann, Omid Hamid, Cancer Immunology Research	2017	543
PD-1 Blockade Expands Intratumoral Memory T Cells Antoni Ribas, Daniel Sanghoon Shin, Jesse M. Zaretsky, Cancer Immunology Research	2016	398
BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy Richard C. Koya, Stephen Mok, Nicholas Otte, Cancer Research Adoptive Cell ImmunotherapyTumor ImmunologyAntitumor ActivityTransferred CellsCancer Immunosurveillance	2012	232
Phase I Trial of Intratumoral Injection of<i>CCL21</i>Gene–Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration Jay M. Lee, Mi-Heon Lee, Edward B. Garon, Clinical Cancer Research	2017	220
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation Arnav Mehta, Yeon Joo Kim, Lídia Robert, Cancer Discovery	2018	177
MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy Julia Reinhardt, Jennifer Landsberg, Jonathan L. Schmid‐Burgk, Cancer Research	2017	157

Page 1